



Management Report 2024

April 2025

The Information

The information in this Management Report for fiscal year 2024 has been prepared by Labiana Health S.A. ("Labiana") in compliance with Article 17 of Regulation (EU) No. 596/2014 on market abuse, Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, and Circular 3/2020 of the BME Growth segment of BME MTF Equity ("BME Growth"). This report contains relevant information about Labiana and constitutes its Integrated Annual Report as of December 31, 2024.

Content of the January-December 2024 Management Report

- I. The Management Report, spanning pages 4 to 40, provides an analysis of the company’s performance and results for 2024, including a comparison with 2023. It was prepared by the Board of Directors on March 26, 2025, in line with CNMV guidelines for listed companies. For comparability purposes, this Directors' Report 2024 includes, together with the audited consolidated financial statements for 2024 and 2023, the income statement and balance sheet for 2023 without the consolidation of the subsidiary Zavod (non-audited data), as this is the accounting criterion established in the accounts from 2024 onwards. The report covers key aspects such as the business model, outlook, risk management, and significant events before and after the close of the fiscal year.
- II. Corporate governance information is detailed in Section 7 of the Management Report (page 28), within the ESG-related policies and practices.

Legal Notice and Forward-Looking Information

The information contained in this Management Report has been prepared by Labiana and includes financial information extracted from the 2024 financial statements of Labiana Health, S.A., corresponding to the period January-December 2024, audited by Auren Auditores, as well as statements regarding future forecasts.

Forward-looking information and statements about Labiana are not historical facts, are based on assumptions that are believed to be reasonable, and are subject to risks and uncertainties, many of which are difficult to predict and are, generally, beyond Labiana's control. Accordingly, shareholders and investors are cautioned that these risks could cause actual results and developments to differ from those initially anticipated in the forward-looking information and projections.

Except for the financial information referred to herein, the information and any of the opinions and statements contained in this document have not been verified by independent third parties and, therefore, no warranty is expressed or implied as to the fairness, accuracy, completeness or correctness of the information or the opinions and statements expressed therein.

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 6/2023, of March 17, of the Securities Markets and Investment Services Law and its implementing regulations. This report does not constitute an offer or solicitation to buy, sell or exchange securities in any jurisdiction.



content

- 1** CEO letter to shareholders
- 2** 2024 at a glance
- 3** Economic environment and the pharmaceutical sector
- 4** Labiana Health, company profile and business model
- 5** Management results for January-December 2024
 - 5.1** Operational and financial results
 - 5.2** Capital management and financing
 - 5.3** Cash Flow generation
- 6** Evolution of business segments and markets in 2024
 - 6.1** Animal Health (CDMO and Own Vademecum)
 - 6.2** Human Health (CDMO and Own Vademecum)
- 7** ESG
- 8** Risk management
- 9** Significant events during and after the reporting period
- 10** R&D activity and registrations
- 11** Foreseeable developments
- 12** Average supplier payment period
- 13** Acquisition and disposal of treasury shares
- 14** Consolidation perimeter
- 15** Labiana Health in the Stock Market
- 16** Glossary
- 17** Contact
- 18** Annexes

1 CEO letter to shareholders

Dear Shareholder,

I am pleased to present Labiana Health’s financial and operational results for the fiscal year 2024—a year marked by progress, strategic decisions, and the commitment of our entire team.

During 2024, we achieved a 13.3% increase in revenue, reaching 66.3 million euros. This growth has also been profitable as we have multiplied by 2.6 times the Adjusted EBITDA of 2013 to reach an amount of 9.7 million euros. At the same time, we have reduced our Net Financial Debt by 26.1%, thus strengthening our financial position without reducing our investment effort.

Undoubtedly, these achievements are the result of key strategic decisions, implemented in the last quarter of 2023. The addition of Sandra Villagrasa as CEO has brought renewed leadership and a strategic vision essential to our evolution. Likewise, the 25 million euros financing agreement signed with Miralta Finance Bank and Blantyre Capital in August 2023 has been instrumental in driving our business plan and improving our capital structure.

The divestment in Serbia during the first half of 2024, reducing our stake in our subsidiary to 10%, has enabled significant financial deleveraging and value creation. This transaction has reduced pro forma consolidated debt by 8.5 million euros and released 0.9 million euros in collateral, strengthening our capital structure without compromising our biologics development and manufacturing capabilities.

In addition, the implementation of the strategic management and operational efficiencies plan in 2023 has resulted in significant improvements in productivity and cost control. This plan has been key to the growth observed in 2024 and lays the foundation for a positive evolution in the future.

Despite this progress, we are aware that much remains to be done. Our focus remains on consolidating and expanding our presence in the animal and human health markets, investing in innovation and strengthening our relationships with customers and strategic partners.

I would like to sincerely thank the continued support of our shareholders, the dedication of our employees and the trust of our customers and partners. Together, we will continue to work to achieve new milestones and ensure sustainable growth for Labiana Health.


Sincerely yours,

Manuel Ramos
CEO of Labiana Health




2 2024 at a glance

MAIN FINANCIAL FIGURES



MAIN OPERATIVE FIGURES



1. Adjusted EBITDA 2023: Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process and the search for advisors (advisors for the entire process). Adjusted EBITDA 2024: Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process, the divestment process in Serbia and the search for financing.

2. Net Financial Debt at 31.12.2024.

For comparability purposes, the variations with respect to 2023 in turnover, Adjusted EBITDA and Net Income are calculated on the same parameter of 2023 without the consolidation of the subsidiary Zavod, non-audited data, as this is the accounting criterion established in the accounts as from the financial year 2024.

MAIN FINANCIAL FIGURES

Turnover

€34.4M

Var. 2023 without Zavod: 15.8%

% Own Vademecum


16.9%

Var. 2023 without Zavod: (2.5) p.p.

% CDMO

35.0%

Var. 2023 without Zavod: 1.4 p.p.




MAIN OPERATIVE FIGURES

Main products

Fosfomycin Trometamol



Precyst



177
Employees

101
MAs

MAIN FINANCIAL FIGURES

€31.8M

Var. 2023 without Zavod: 21.3%

15.2%

Var. 2023 without Zavod: (0.6) p.p.

32.8%

Var. 2023 without Zavod: 1.7 p.p.



Labiprofen



Labimycin



Tolfelab



Buprelab



Tilolab




193
Employees


496
MAs

2 2024 at a glance

The 2024 results show a very positive evolution of the company with double-digit growth in all its margin lines, in some cases very significant, as well as the strengthening of its capital structure, with an evident reestablishment of its activity.



The management and operational measures adopted during the previous year to counteract the effects of an IPO in a complicated global economic and financial environment, including the appointment of Sandra Villagrasa as Group General Manager, as well as the financing agreement with Miralta Finance Bank, S.A. and Blantyre Capital Limited, have enabled the company to close the year with positive results and to maintain the objectives established in its Strategic Plan.

On the one hand, the divestment operation in Serbia has allowed deleveraging and value creation through a capital increase dilution of 3 million euros, which has placed the stake in the Serbian subsidiary at 10%. This dilution has led to the exit of this subsidiary from the Group's consolidation perimeter, which in turn has led to a reduction of the pro forma consolidated debt at the end of 2024 by 8.5 million euros, as well as the release of 0.9 million euros of guarantees from Labiana Life (division that manages the animal health business). All this has generated a strengthening of the capital structure without sacrificing the development and

manufacturing capabilities of biological products and its commercial link with Eastern Europe.

On the other hand, the implementation of the various management and operational measures have enabled the company to close the 2024 financial year with a turnover of 66.26 million euros, which represents an increase of 13.3% compared to the consolidated data published in the same period of 2023. However, when the turnover is compared to the 2023 data after deducting the contribution of the Serbian subsidiary, it stands at 18.4%.

Both divisions (animal health and human health) have experienced double-digit growth in 2024 compared to the data published in the same period of the previous year.

By business areas, in the case of human health, the area of proprietary products has been affected because some of our customers sell in regulated markets where, since the local government sets the price, they have not been able to apply the cost increases of our products. This has reduced the turnover of this


area, which closed the year with a slight increase of 3.4% compared to the previous year. On the other hand, the CDMO area performed well, with a 23.3% increase in revenues compared to 2023.

In the case of animal health, the CDMO area has a similar behavior to that of human health, closing the year with an increase of 25.0% over the consolidated data published in 2023. As for the own product, it is in this area where the deconsolidation of the Serbian subsidiary has the greatest impact since, if we compare the closing of 2024 with the data published in 2023, the own product of animal health would close with 11.5% less, however, when comparing with the data of 2023 once the contribution of the Serbian subsidiary is discounted, what is observed is that 2024 grows by 13.9% compared to the data of 2023 without Serbia.

By geographical areas, Spain and Europe are consolidated as the main markets for both proprietary products and CDMO in both animal and human health.

2024

Listing milestones



3 Economic environment and the pharmaceutical sector

The pharmaceutical sector is key to people's health and quality of life, but it is also a key industrial sector for the world's major economies and plays an essential role in medical and scientific progress. Its estimates for growth in the global volume of medicines used between 2023 and 2028 are 2.3% per year¹.

Thus, the value of the pharmaceutical market in 2028 is estimated to reach 2.3 trillion dollars, with average annual increases of between 5 and 8%.

The pharmaceutical sector in Europe employs around 900,000 people directly, and approximately three times more indirectly. In 2021 it invested 24,533 million euros in research and development (R&D&I), being fundamental in the growth and improvement of employment figures in our country in recent years and forming part of the modernization of the productive fabric.

Spain is the fourth largest pharmaceutical market in the European Union (EU) in terms of turnover and the ninth largest worldwide. Spain currently has 174 drug production plants. Of this total, 106 plants are dedicated to the synthesis of drugs for human use (of which 12 are for biological drugs), 46 plants to produce active ingredients and 22 for veterinary use.

This implementation places Spain as one of the European countries with the greatest production potential at a time when medicines have proven to be a strategic and security asset for countries.

In 2023, the country exported pharmaceutical products worth 21.9 billion euros, the third largest domestic export by amount, while the value of imported pharmaceutical products amounted to 24.8 billion euros.

The pharmaceutical industry in Spain generates more than 270,000 jobs (56,000 of them direct) of high quality, qualified, egalitarian and with a high diversity. The highest hiring rates are found among young people and those over 50 years of age.

As far as animal health and nutrition is concerned, in 2024, the Spanish industry had a global turnover of 2,276 million euros, which represents a growth of 8.54% over the previous

year. Of this figure, 1,382 million euros corresponded to the domestic market, which grew by 7.56%, while exports to more than 90 countries grew again, reaching 894 million euros, an increase of 10.10%.

As for the CDMO segment, according to data from Mordor Intelligence, the global CDMO market size in 2024 is estimated at 238.47 billion dollars and is expected to reach 330.36 billion dollars by 2029, growing at a CAGR of 6.74% during the forecast period (2024-2029).

Likewise, the same consulting firm estimates that the global generic drug market size will be 431.10 billion dollars in 2025 and is expected to reach \$530.32 billion dollars by 2030, at a CAGR of 4.23% during the forecast period (2025-2030).

The increasing prevalence of chronic diseases has spurred the demand for affordable drugs, which has driven the generic drug market. Their lower cost, compared to branded alternatives, is a significant factor driving their adoption in developing and developed economies. In addition, as patents on best-selling drugs expire, the market is witnessing an increase in the development of generic versions, further driving the growth of the generic drug market.



1. Source: https://www.sanidad.gob.es/areas/farmacia/infoIndustria/docs/Estrategia_de_la_industria_farmaceutica.pdf

4 Labiana Health, company profile and business model

Labiana Health is the parent company of a Spanish pharmaceutical group dedicated to the development, manufacture and marketing of medicines in the areas of animal and human health.



Its business mission is to position itself as a reference group in the human and animal health markets.

Since its foundation in 1958 as a group specialized in animal nutrition products, the Group has undergone a continuous process of growth, diversification and internationalization, becoming today a pharmaceutical group of reference that stands out as:

- CDMO (Contract Development and Manufacturing Organization) providing third party drug development and manufacturing services in a wide variety of presentations, specializing in solid, sterile, solution and lyophilized dosage forms and special authorizations such as psychotropic, narcotic and hormonal drugs. CDMO (animal health + human health) currently represents 44.97 million euros of Labiana's total turnover in 2024.
- Manufacturer of a wide range of proprietary products for both animal and human health to reach a sales figure of 21.29 million euros in 2024. Particularly noteworthy is Fosfomycin Trometamol (human health), a product that has been key to Labiana's development and growth in recent years.

In turn, both in human and animal health, Labiana develops a multidisciplinary activity based on:

- Research and development (R&D) of new proprietary and third-party drugs, based on the "Stage Gate" methodology. Labiana carries out both galenic and analytical development, for which it has its own laboratories. Manufacture of both chemical and biological drugs from:
 - Development and optimization of formulations, design of production processes for new products.
 - Transfers of already authorized products.
 - Manufacture of sterile products via aseptic production or terminal sterilization.
 - Non-sterile manufacturing and filling of oral and topical liquid and oral solid forms.
 - Development and manufacture of bacterial vaccines.
- Regulatory services: Labiana has extensive "expertise" in pharmaceutical product registration procedures for proprietary and third-party products, both for the registration of dossiers worldwide and for processing the change of manufacturer of a drug for CDMO clients, thus making it easier for new pharmaceutical companies to start working with Labiana as a manufacturer of their products..

Labiana currently consists of four main operating companies employing 370 employees, operates two production centers in Spain, works with more than 300 leading national and international pharmaceutical groups and has a proprietary portfolio of more than 50 products, among which Fosfomycin Trometamol (antibiotic for urinary tract infections) stands out in human health.


Currently, the products manufactured by the Group are marketed in more than 114 countries worldwide, thanks to its GMPs ("Good Manufacturing Practice") manufacturing plants in Spain, its international subsidiaries in Turkey and Mexico, its growing network of multinational customers and its licensing agreements with international distributors for the sale of its own products.

4

Labiana Health, company profile and business model

The group is structured as follows to address its two relevant markets, animal health and human health.

Business	Animal Health	Human Health
Main companies	<div> <div> <div> LABIANA México </div> </div> </div>	<div> </div>
Employees at of 31/12/24	<div> 188 <div>4</div> <div>1</div> </div>	<div> 177 </div>
Main Customers	<div> </div>	<div> </div>
Manufacturing plants	<div> 1 plant in Terrassa (EU-GMP) </div>	<div> 1 plant in Corbera de Llobregat (Full EU-GMP) </div>
Main Own Products	<div> <div> Labiprofen <div> </div> </div> <div> Labimycin <div> </div> </div> <div> Tolfelab <div> </div> </div> <div> Buprelab <div> </div> </div> <div> Tilolab <div> </div> </div> </div>	<div> <div> Fosfomicina <div> </div> </div> </div>
Turnover 2024	<div> €31,849,984.17 (48.1% total Group) </div>	<div> €34,406,772.59 (51.9% total Group) </div>



5 Management results for January-December 2024

5.1 Operational and financial results

The year 2024 has been a year marked by both the corporate operation with respect to the subsidiary in Serbia, which led to its exit from the Group's consolidation perimeter, and by the implementation of different management and operational measures that have enabled the company to obtain positive results and maintain the objectives established in its Strategic Plan..



In fact, all this has led to consolidated revenues in this financial year amounting to 66.26 million euros, which represents an increase of 13.3% compared to the consolidated data published in the same period of 2023. When we make the comparison without the contribution of the Serbian subsidiary in the 2023 results, the comparable organic growth becomes 18.4%.

By business segment, both divisions (animal health and human health) have experienced double-digit growth in 2024 compared to the data published in the same period of the previous year. The human health division grew by 16.0% compared to 2023. The animal health division also shows an upward trend, with an increase of 10.6% compared with the data published in 2023. Excluding the impact of the Serbian subsidiary in the previous year, whose activity is in animal health, this growth rises to 18.4%.

By business area, in the case of human health, the CDMO area has experienced a notable growth of 23.3% in revenues. However, the proprietary product area has been affected by the fact that some of our customers have not been able to apply the cost increases of our products because they are selling in regulated markets where the local government sets the price. This has conditioned the sales growth of our own product area, maintaining it at 3.4%.

In the case of animal health, the CDMO area closes with an increase of 25.0% over the consolidated data published in 2023. As for the proprietary product, it could be thought that 2024 closes with a lower turnover if what is compared with the consolidated data published in 2023. However, when comparing with the data for the same period, but excluding the data from the Serbian subsidiary, what we observe is that the company's own product experiences an increase of 13.9%.

These results can be explained by the fact that the Serbian subsidiary's contribution to the total was mainly its own animal health product.

In terms of geographic areas, in animal health, the fastest growing areas are Europe and Spain, with LATAM recovering its own product activity and returning to sales figures close to 2022.

This growth in revenue has also been profitable, as the company recorded a very favorable evolution in all its margin lines, Gross Margin, EBITDA, EBIT and Net Income in 2024.

Specifically, the gross margin gains three points when compared to 2023 without the consolidation of the Serbian subsidiary, from 57% to 60%. This evolution favors EBITDA performance not only because it contributes to gross margin growth because of higher sales for the year, but also because these higher sales are achieved with a higher gross margin, as can be seen in the waterfall graph of Adjusted EBITDA evolution for 2024.

As for EBITDA, the measures taken by the company in terms of cost optimization, revenue diversification and the search for operating efficiencies, together with the exclusion of the Serbian subsidiary from the scope of consolidation, were mainly responsible for the company's EBITDA reaching 9,43 million euros (9.68 million euros in adjusted terms) compared to the 3.29 million euros published for the same period of 2023, or the 4.08 million euros that would have been obtained in that period excluding the data corresponding to the Serbian subsidiary, i.e. a 160.9% growth.

In terms of operating profit (EBIT), this has improved significantly, from a negative result published in 2023 of 1.58 million euros to a positive result of 4.96 million euros in 2024. This is mainly due to the increase in EBITDA and the reduction in depreciation, amortization and impairments.

Financial expenses increased significantly in 2024 compared to the same period in 2023, with an increase of 47.2%, from 3.29 million euros in 2023 to 4.84 million euros in 2024. The main reasons are the refinancing costs linked to the agreement with Miralta Finance Bank, S.A. and Blantyre Capital Limited.


5 Management results for January-December 2024

5.1 Operational and financial results

Consolidated income statement	Figures expressed in euros				
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.	2023 WITHOUT Zavod*	% Var. 2024 vs 2023 WITHOUT Zavod
Net turnover	66,256,756.76	58,462,364.53	13.3	55,966,664.69	18.4
Var. Inventories of finished goods and work in progress	261,538.21	(1,307,091.37)	c.s.	(825,887.94)	c.s.
Work carried out by the company for its assets	1,117,701.71	1,235,530.36	(9.5)	1,235,530.36	(9.5)
Procurements	(26,693,136.29)	(24,051,840.02)	11.0	(23,218,511.93)	14.96
Other operating income	0.00	12,349.84	--	315.00	--
Personnel expenses	(20,430,895.12)	(19,103,250.04)	6.9	(18,173,395.53)	12.4
Other operating expenses	(11,077,172.17)	(11,954,275.10)	(7.3)	(10,908,340.32)	1.5
Gross operating profit (EBITDA)	9,434,793.10	3,293,788.20	186.4	4,076,374.33	131.5
Depreciation of fixed assets	(4,251,851.77)	(5,083,099.18)	(16.4)	(4,549,768.49)	(6.5)
Allocation of subsidies for non-financial fixed assets and others	13,955.62	13,955.63	n.s.	13,955.63	n.s.
Impairment and gains/losses on disposal of fixed assets	(137,813.36)	328,288.36	c.s.	392,431.95	c.s.
Other results	(99,463.21)	(135,367.17)	(26.5)	(133,778.67)	(25.7)
Operating profit (EBIT)	4,959,620.38	(1,582,434.16)	c.s.	(200,785.25)	c.s.
Financial income	20,607.06	5,325.89	n.s.	41,855.83	(50.8)
Financial expenses	(4,838,927.10)	(3,288,059.58)	47.2	(2,534,138.58)	90.9
Foreign exchanges differences	(66,840.55)	54,043.80	c.s.	31,609.39	c.s.
Variation in fair value of financial instruments	(563.00)	27,388.69	c.s.	27,388.69	c.s.
Impairment and gains/losses on disposal financial instruments	(103,893.80)	(481,799.25)	(78.4)	(2,279,014.84)	(95.4)
Profit/loss before tax	(29,997.01)	(5,265,534.61)	(99.4)	(4,913,084.76)	(99.4)
Income tax	236,502.66	775,967.03	(69.5)	755,492.58	(68.7)
Net consolidated profit/loss	206,505.65	(4,489,567.58)	c.s.	(4,157,592.18)	c.s.
Net profit attributable to minority interests	46,943.96	(66,799.89)	c.s.	(66,799.89)	c.s.
Total net income attributable to the Company	159,561.69	(4,422,767.69)	c.s.	(4,090,792.29)	c.s.
Adjusted EBITDA¹	9,681,290.06	3,710,774.63	160.9	4,493,360.76	115.5
Adjusted EBIT²	5,206,117.34	(1,165,447.73)	c.s.	216,201.18	n.s.

1. Adjusted EBITDA 2023: Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process and the search for advisors (advisors for the entire process). Adjusted EBITDA 2024: Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process, the divestment process in Serbia and the search for financing.

2. Adjusted EBIT 2023: Earnings before interest and taxes deducting extraordinary expenses derived from the Miralta process and the search for advisors (advisors for the entire process). Adjusted EBIT 2024: Earnings before interest and taxes after deducting the extraordinary expenses derived from the Miralta process, the divestment process in Serbia and the search for financing.




ah: Animal Health | hh: Human Health

* 2023 data without Zavod non-audited.

5 Management results for January-December 2024


5.1 Operational and financial results

Turnover Percentage Distribution by Business Segment 2024



**2024 Turnover
€66.3M**



Turnover Percentage Distribution by Business Segment 2023



**2023 Turnover
€56.0M**

5 Management results for January-December 2024

5.1 Operational and financial results




5 Management results for January-December 2024

5.1 Operational and financial results

Adjusted EBITDA evolution 2024 vs. 2023


Figures expressed in euros



* 2023 data without Zavod non-audited.

5 Management results for January-December 2024

5.2 Capital management and financing



Current assets have experienced a slight decrease of 1.2% with respect to the data published in 2023, highlighting the inventory items with a reduction of 13.67% because of the increase in sales at the end of 2024, and a decrease in the trade and other receivables item by 18.9%, reflecting a more efficient collection management. All this has had a positive effect on the cash item, which has increased by 127.7% at the end of 2024.

From the point of view of capital structure and financing, the company has made a significant effort to reduce and reorganize its debt. In this regard, in addition to the financing agreement reached in mid-2023 with Miralta Finance Bank, S.A. and Blantyre Capital Limited, it is worth highlighting in this fiscal year 2024 the corporate operation that has led to the reduction of the stake in the subsidiary in Serbia to 10% through a capital increase dilution of 3 million euros, which has facilitated a significant deleveraging in Labiana's balance sheet.

Indeed, this operation entails the exit of this subsidiary from the group's consolidation perimeter, which implies the reduction of the consolidated debt compared to that at the end of 2023 by 8.5 million euros (6.68 million euros of financial debt and 1.82 million euros of commercial debt), as well as the release of 0.9 million euros of guarantees from Labiana Life (division that manages the animal health business).

As a result, the net financial debt to Adjusted EBITDA coverage ratio for the period was 2.96x, which represents a significant drop compared to the data published at the end of fiscal year 2023 of 10.45x. All this generates a strengthening of the capital structure without sacrificing the development and manufacturing capabilities of biological products and its commercial link with Eastern Europe.

Consolidated Balance sheet	Figures expressed in euros				
	31.12.24 WITHOUT Zavod	31.12.23 WITH Zavod	% Var.	31.12.23 WITHOUT Zavod*	% Var. 2024 vs 2023 WITHOUT Zavod
Non-current assets	23,306,028.19	30,141,714.91	(22.7)	22,712,662.85	2.6
Intangible assets	6,026,391.36	7,678,689.90	(21.5)	7,406,387.87	(18.6)
Property, plant and equipment	12,684,246.30	19,772,557.07	(35.8)	12,004,270.45	5.7
Long-term financial investments	2,114,936.04	889,354.21	137.8	1,500,890.80	40.9
Deferred tax assets	2,480,454.49	1,801,113.73	37.7	1,801,113.73	37.7
Currents assets	28,695,939.81	29,055,192.39	(1.2)	27,226,339.17	5.4
Inventories	10,678,956.68	12,365,756.11	(13.6)	10,967,698.15	(2.6)
Trade and other receivables	10,937,135.89	13,484,720.45	(18.9)	13,110,683.74	(16.6)
Short-term financial investments	159,000.25	14,386.14	n.s.	70,537.18	125.4
Short-term accruals	182,832.93	157,335.11	16.2	154,463.78	18.4
Cash and cash equivalents	6,738,014.06	2,959,476.37	127.7	2,922,956.32	130.5
Total assets	52,001,968.00	59,196,907.30	(12.2)	49,939,002.02	4.1
Total equity	2,568,050.13	3,403,231.88	(24.5)	2,653,924.93	(3.2)
Non-current liabilities	27,275,343.16	31,021,495.62	(12.1)	25,295,674.53	7.8
Long-term provisions	5,590.60	76,261.41	(92.7)	5,590.60	n.s.
Long-term financial debt	27,236,690.89	30,587,784.70	(11.0)	25,252,370.37	7.9
Deferred tax liabilities	33,061.67	357,449.51	(90.8)	37,713.56	(12.3)
Current liabilities	22,158,574.71	24,698,661.60	(10.3)	21,989,402.56	0.8
Short-term financial debt	8,153,138.54	11,132,438.21	(26.8)	9,898,265.05	(17.6)
Trader and other payables	13,505,436.17	12,968,961.71	4.1	11,496,836.51	17.5
Short-term accruals	500,000.00	597,261.68	(16.3)	594,301.00	(15.9)
Total liabilities	52,001,968.00	59,196,907.31	(12.2)	49,939,002.02	4.1


* 2023 data without Zavod non-audited.

5 Management results for January-December 2024

5.2 Capital management and financing


Balance Structure as of 31.12.204 (without Zavod) and as of 31.12.2023 (with Zavod)

Figures expressed in million euros



Gros Debt Structure as of 31.12.204 (without Zavod) and as of 31.12.2023 (with Zavod)

Figures expressed in million euros




5 Management results for January-December 2024

5.2 Capital management and financing


Net Financial Debt Evolution and NFD/Shareholder Equity

Figures expressed in euros



Indebtedness and Debt Coverage

Figures expressed in euros



5 Management results for January-December 2024

5.3 Cash flow generation

2024 closes with a pre-tax result for the year that goes from a negative 5.26 million euros in 2023 to a negative 0.03 million euros at the end of this fiscal year. This is due to several factors, among which are the increase in sales, the reduction of costs, the set of operational improvements introduced in the company, as well as the reduction of depreciation and impairments.

Cash flows have increased from 0.45 million euros in 2023 to 3.78 million euros in 2024.


Cash flows from operating activities have gone from negative 1.8 million euros in 2023 to negative 7.20 million euros in 2024, mainly due to lower short-term operating cash requirements, with the debtors' item going from negative 1.64 million euros in 2023 to negative 2.86 million euros in 2024 thanks to greater efficiency in collection management. Improvements in inventory management have also been rewarded, with this item going from 1.12 million euros in 2023 to 1.20 million euros negative in 2024.

Cash flows from investing activities have increased by 96%, increasing CapEx from 2.03 million euros in 2023 to 3.99 million euros in 2024, highlighting in this item the investments being made to increase the Group's capacity and productivity improvements as well as the investments in Labiana Pharmaceuticals to adapt the plant to the new GMP Annex I sterile regulations.

Likewise, free cash flow has increased by more than 7 million euros, from 3.64 million euros of negative cash flow in 2023 to 3.64 million euros in 2024, indicating a significant improvement in the company's ability to generate free cash after covering its operating expenses and investment effort.

Consolidated Cash Flow Statement 2024

Figures expressed in euros



5

Management results for January-December 2024

5.3

Cash flow generation

Cash Flow Statements

Cash flow from operating activities	Figures expressed in euros		
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.
Consolidated profit before tax	(29,997.01)	(5,265,534.61)	(99.4)
Adjustments to consolidated result	9,026,952.18	8,368,174.31	7.9
Depreciation of fixed assets	4,251,851.77	5,086,021.11	(16.4)
Impairment losses	946,623.22	64,807.18	n.s.
Changes in provisions	0.00	(6,072.25)	--
Imputation of subsidies	(13,955.62)	0.00	--
Profit/loss on disposal of fixed assets	(117,272.23)	21,528.12	c.s.
Financial income	(20,607.06)	(5,325.89)	n.s.
Financial expenses	4,838,927.10	3,288,059.58	47.2
Variation in fair value of financial instruments	563.00	(27,388.69)	c.s.
Other income and expenses	(859,178.00)	(53,454.85)	n.s.
Changes in working capital	3,100,804.18	(1,575,269.08)	c.s.
Inventories	(1,195,334.80)	1,118,380.70	c.s.
Debtors and other receivables	2,860,212.02	(1,642,848.09)	c.s.
Other currents assets	(28,369.15)	314,741.03	c.s.
Creditors and other accounts payable	1,558,597.11	(1,962,804.41)	c.s.
Other current liabilities	(94,301.00)	597,261.69	c.s.
Other consolidated cash flow from operating activities	(4,905,476.48)	(3,338,987.87)	46.9
Interest payments	(4,838,927.10)	(3,288,059.58)	47.2
Interest charges	20,607.06	5,325.89	n.s.
Income tax payments (receipts)	(87,156.44)	(47,482.99)	83.6
Other payments (receipts)	0.00	(8,771.19)	--
Total cash flow from operating activities	7,192,282.87	(1,811,617.25)	c.s.

5

Management results for January-December 2024

5.3

Cash flow generation

Cash Flow Statements

	Figures expressed in euros		
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.
Cash flow from investing activities			
Payments for investments	(4,015,466.26)	(2,915,180.35)	37.7
Company and associated companies	(36,520.05)	0.00	--
Intangible assets	(31,406.72)	(1,191,999.39)	(97.4)
Property, plant and equipment	(3,015,711.01)	(1,658,211.28)	81.9
Investment properties	0.00	0.00	--
Other assets	(931,828.48)	(64,969.68)	n.s.
Proceeds from divestments	30,059.11	881,890.60	(96.6)
Intangible assets	0.00	309,952.19	--
Property, plant and equipment	1,069.11	15,532.04	(93.1)
Investment properties	0.00	0.00	--
Other assets	28,990.00	556,406.37	(94.8)
Total cash flow from investing activities	(3,985,407.15)	(2,033,289.75)	96.0

	Figures expressed in euros		
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.
Cash flow from financing activities			
Proceeds and payments for equity instruments	(158,929.08)	1,097,124.05	c.s.
Issue of equity instruments	0.00	1,255,717.27	--
Acquisition of treasury stocks	(158,929.08)	(158,593.22)	0.2
Proceeds and payments for financial liability instruments	730,591.06	3,200,377.53	(77.2)
Issuance of bank borrowings	0.00	19,381,605.93	--
Other debt issuance	4,373,338.41	165,425.38	n.s.
Repayment and amortisation of bank debt	(3,032,109.19)	(15,584,334.31)	(80.5)
Repayment and redemption of other debts	(610,638.16)	(762,319.47)	(19.9)
Total cash flows from financing activities	571,661.98	4,297,501.58	(86.7)
Net increase/decrease in cash or cash equivalents	3,778,537.70	452,594.58	n.s.
Cash or cash equivalents at the beginning of the year	2,959,476.37	2,520,837.93	17.4
Cash or cash equivalents at the end of the year	6,738,014.06	2,959,476.37	127.7

	Figures expressed in euros		
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.
Free cash flow calculation			
EBITDA	9,434,793.10	3,293,788.20	186.4
CapEx for the period	(3,985,407.15)	(2,033,289.75)	96.0
Investment in working capital	3,100,804.18	(1,575,269.08)	c.s.
Net financial interest payment	(4,818,320.04)	(3,282,733.69)	46.8
Payment of corporate income tax	(87,156.44)	(47,482.99)	83.6
Free Cash Flow	3,644,713.65	(3,644,987.31)	c.s.

6 Evolution of business segments and markets in 2024

6.1 Animal Health

From an operational point of view, during 2024 the animal health division (Labiana Life Science), has 496 registrations in force with presence in more than 86 countries. Thirty-five new registrations have been approved and another 50 are in the pipeline at year-end, of which 34 are expected to be successfully closed during 2025.

Own Product: Following the trend of the first half of the year, sales of own product would appear to have declined by 11.5% compared to the consolidated data published for the same period of the previous year. However, when the sales performance for the year is analyzed against the data for the same period excluding the data of the Serbian subsidiary, this area has actually experienced a remarkable growth of 13.86%.

By geographic markets, the most striking values are in Spain and Europe, where the company's own product is consolidating and growing.

Due to proximity, political stability and market prices, Labiana is betting on the European markets in its own vademecum, as indicated by the high regulatory activity of the company in this geographic area in which this year it has obtained the approval of 25 new market authorizations in this territory (71.4% of the total new MAs that have been approved in the animal health division during 2024), another 14 new MAs have been submitted (representing 58.3% of the total new MAs submitted in 2024),4% of the total number of MAs that have been approved in the animal health division during 2024), another 14 new MAs have been submitted (representing 58.3% of the total new MAs submitted) and it is expected that during 2025 the company will be able to add another 34 new MAs to the total number of active market authorizations it has in the EU.


It is also worth mentioning that the company has entered the Canadian market, where it expects to grow in the coming months. Likewise, the Algerian market, which had been paralyzed due to international bureaucratic issues, has resumed its activity.

CDMO: The CDMO division closed the period with sales of 21.76 million euros, 25% more than in the same consolidated period published in 2023.

Of note in this period is the entry of 6 new CDMO projects in 2024, 4 of which are already in production and 2 in the transfer phase. During 2024, 7 of the 11 projects that entered in 2023 have also been put into production. The year closed with a total of 29 CDMO customers, 2 of which are new.

By geographic markets, as with its own products, the company is growing in Europe and Spain, which are consolidating as the main markets for both CDMO and its own products.

The PETS division continues to grow from a turnover of 1,037 thousand euros in 2023 to 1,129 thousand euros in 2024, representing an increase in sales 8.9%.



6 Evolution of business segments and markets in 2024

6.2 Human Health

The human health segment performed very favorably in 2024, a year in which, overall, it achieved sales of 34.41 million euros, 16% more than in 2023.

Own Product: In this fiscal year 2024, the own product area of human health has been affected because some of our customers sell in regulated markets in which, since the local government sets the price, they have not been able to apply the cost increases of our products. This has reduced turnover in this area, which closed the year with a slight increase of 3.4% over the previous year.

By markets, Spain remained stable, while in Europe the effect of market regulation was felt in this area, closing the year with a 20% decrease in sales.


In North America, the market is consolidating and continues to grow in both the Canadian and U.S. markets.

In LATAM they remain practically stable and in Rest of the World they decrease slightly because the war and the blockade in Russia.

CDMO: CDMO closed the year with a turnover of 23.20 million euros, 23.3% more than the previous year.

By geographic markets, Spain and Europe experienced significant growth of 12% and 27%, respectively, mainly due to the growth in customers, both in new developments and historical products. The Rest of the World remained at the same levels as in 2023.

In general terms, the human health business unit closed 2024 with important achievements in terms of growth of its own product, with 6 new Market Authorizations approved and 23 in the pipeline at the end of the year, of which 21 are expected to be approved during 2025.



6 Evolution of business segments and markets in 2024

Distribution of net sales by business segments	Figures expressed in euros				
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.	2023 WITHOUT Zavod*	% Var. 2024 vs 2023 WITHOUT Zavod
Turnover	66,256,756.76	58,462,364.53	13.3	55,966,664.69	18.4
Animal Health	31,849,984.17	28,805,378.51	10.6	26,264,262.59	21.3
CDMO	21,764,367.49	17,406,306.11	25.0	17,406,306.11	25.0
Own vademecum	10,085,616.68	11,399,072.40	(11.5)	8,857,956.48	13.9
Human Health	34,406,772.59	29,656,986.02	16.0	29,702,402.10	15.8
CDMO	23,203,644.40	18,817,544.09	23.3	18,817,544.09	23.3
Own vademecum	11,203,128.19	10,839,441.93	3.4	10,884,858.01	2.9

% Distribution of net sales by business segments	2024 WITHOUT Zavod	2023 WITH Zavod	Var. p.p.	2023 WITHOUT Zavod*	Var. p.p. 2024 vs 2023 WITHOUT Zavod
Turnover	100.00	100.00	--	100.00	--
Animal Health	48.07	49.27	(1.2)	46.93	1.1
CDMO	32.85	29.77	3.1	31.10	1.7
Own vademecum	15.22	19.50	(4.3)	15.83	(0.6)
Human Health	51.93	50.73	1.2	53.07	(1.1)
CDMO	35.02	32.19	2.8	33.62	1.4
Own vademecum	16.91	18.54	(1.6)	19.45	(2.5)



* 2023 data without Zavod non-audited.

6 Evolution of business segments and markets in 2024

Distribution of net sales by geographics	Figures expressed in euros				
	2024 WITHOUT Zavod	2023 WITH Zavod	% Var.	2023 WITHOUT Zavod*	% Var. 2024 vs 2023 WITHOUT Zavod
Turnover	66,256,756.76	58,462,364.53	13.3	55,966,664.69	18.4
Spain	18,620,714.62	16,089,744.97	15.7	16,034,074.40	16.1
EU ex-Spain	39,837,939.36	35,985,883.70	10.7	33,594,448.97	18.6
USA	4,536,425.22	2,964,236.37	53.0	2,964,236.37	53.0
Rest of the world	3,261,677.56	3,422,499.48	(4.7)	3,373,904.95	(3.3)

% Distribution of net sales by geographics	2024 WITHOUT Zavod	2023 WITH Zavod	Var. p.p.	2023 WITHOUT Zavod*	Var. p.p. 2024 vs 2023 WITHOUT Zavod
Turnover	100.00	100.00	--	100.00	--
Spain	28.10	27.52	0.6	28.65	(0.5)
EU ex-Spain	60.13	61.55	(1.4)	60.03	0.1
USA	6.85	5.07	1.8	5.30	1.6
Rest of the world	4.92	5.85	(0.9)	6.03	(1.1)



* 2023 data without Zavod non-audited.

7

ESG

In compliance with Law 11/2018 amending the Commercial Code, the revised text of the Capital Companies Act approved by Royal Legislative Decree 1/2010, of July 2, and Law 22/2015, of July 20, on Auditing of Accounts, regarding non-financial information and diversity, Labiana has undergone verification by an independent third party of the non-financial information statements corresponding to fiscal year 2024.

Based on the evidence gathered during the audit, the following findings per standard were found:

Standard	Strengths	Deviations	Remarks	Opportunities for Improvement
Law 11/2018	1	X	X	X

This deviation was subsequently corrected and the corresponding verification and inclusion of the EINF 2024 was approved by the Board of Directors on March 26, 2025.

The full ESG report is published and accessible to the public through the shareholders and investors section of the company's website. The following are some of the most noteworthy aspects of the report:

1. Regarding the carbon footprint, in the course of 2024, Labiana has reduced its carbon footprint by 0.20%. The following scopes have been considered for the measurement:
- Scope 1: Direct emission sources resulting from activities that the organization controls, including the combustion of hydrocarbons for process units.

- Scope 2: Indirect sources originating from the purchase of electricity (includes electricity used for process units).
2. As for the Plan to Reduce Electricity Consumption during the year 2024 work has continued along the same lines, replacing traditional luminaires with low consumption/LEDS luminaires..

Most of our electricity consumption comes from manufacturing our products and doing so in a way that allows us to ensure the quality and safety of our products. During the year 2024, we have continued to implement measures to minimize energy consumption, which has meant a decrease of 1.46% compared to 2023, despite having increased production in the two production plants.

It is worth mentioning the project for the installation of photovoltaic panels that will be executed during the first quarter of 2025 at the Terrassa plant. This shows the company's commitment to the environment, allowing us to modify the pool of our energy consumption, increasing the use of energy from renewable sources.

3. The CO2 emissions reduction plan aims to reduce the consumption of fossil fuels that power the company's vehicles and forklifts. To this end, the following measures have been taken: a) The company maintains the objective of gradually converting the fleet to more sustainable vehicles. Currently, 50% of the vehicle fleet is made up of hybrid models. This reflects the company's commitment to continue advancing in the adoption of more environmentally friendly technologies, thus contributing to the global reduction of greenhouse gas emissions. b) 100% electric or manual forklift trucks.
4. Currently, 100% of the paper and cardboard and 100% of the wood that is managed as waste goes to recovery.

5. To give a second life to the shredded paper that leaves the facilities, it is being sent to centers that use it for animal welfare, thus contributing to a circular economy that favors greater sustainability in the use of resources.
6. In 2024, a total of 400.30 tons of waste was generated. Of the waste managed in Spain, 32.50% is classified as hazardous waste. In addition, 30.23% of the waste managed was recoverable, thus maintaining the line of work of previous years.
7. 7. In 2024, the #LabianaIncorpora project continues, which brings together all the company's initiatives to:
- Promoting job opportunities for young people and access to their first job.

• Hiring of people at risk of social exclusion.

• Encouraging the incorporation of people from the area. Achieving great benefits such as minimizing the stress of workers, contributing to family reconciliation, facilitating a better use of free time and reducing the environmental impact by reducing the distance of travel to the workplace.
8. Labiana is committed to quality and labor stability. Proof of this is that more than 93% of the workforce has a permanent contract, 100% of the contracts are full-time. At the end of 2024, the workforce totaled 370 employees, 59% of whom are women. By age group, the majority are between 31 and 50 years of age.
9. Equality Plan 2020-2024 whose objective is to empower and promote the social, economic and political inclusion of all people regardless of age, sex, disability, race, ethnicity, origin, religion or economic or other status. This plan was approved in 2019 and in 2021 the plan for the years 2020-

2023 was registered. Currently, the procedures for updating the plan for 2025 have already been initiated.

10. During fiscal year 2024, the reconciliation measures adopted will be maintained, such as the possibility of having Friday afternoons off or promoting schedule changes, reconciliation at the employee's request or facilitating the modification of schedules on an individual basis.

8 Risk management

The Group's activities are exposed to different types of financial risks, mainly credit, liquidity and exchange rate risks.

1. Credit Risk:

The Group's credit risk is mainly attributable to its trade payables. Amounts are reflected in the balance sheet net of provisions for bad debts, estimated by the Group's management based on the experience of previous years and its assessment of the current economic environment.

The Group has a significant concentration of credit risk since it works basically with four large multinationals in the sector. However, these are fully solvent companies with which the Group has been working for a long time, and therefore the credit risk is very diluted.

2. Liquidity Risk:

During the previous year, the Company reached a financing agreement with the investment bank, Miralta Finance Bank S.A. This agreement improved the Company's cash position, which was in a very delicate situation.

As a result, the Group has been able to negotiate with its creditors new debt refinancing schedules and conditions; and, additionally, it is currently in negotiations with several investment entities to obtain new financing formulas that will allow the Group to meet its present and future payment obligations, its investment needs and to continue with the normal development of its business.

All this has led to a normalization of the group's operational management, reflected in a substantial improvement of the group's EBITDA in this audited period. This improvement is expected to continue in the coming year, which would guarantee the non-existence of a liquidity risk for the next 12 months.

3. Exchange Rate Risk:

The Group operates internationally and, therefore, is exposed to exchange rate risk from foreign currency transactions, especially the U.S. dollar. The exchange rate risk arises from future commercial transactions, assets and liabilities recognized in businesses. The Group does not use any type of hedging as it considers that there is not a high risk given the average collection period of the customers with whom it operates in foreign currencies. In addition, most transactions are carried out in low volatility currencies.

4. Interest Rate Risk:

The Group has financial indebtedness, both with banks and with third parties, the financial cost of which is closely linked to the evolution of market interest rates.

Given the current international context of continuously falling interest rates, the Company is optimistic about reducing its financial costs.

In any case, the Company is constantly monitoring the evolution of interest rates and studying possible measures to manage its risk in the event of a new upward trend.

For this reason, the Company reserves the right to take the appropriate decisions based on its analysis and the evolution of the financial market, always in line with its financial policies and objectives.

9 Significant events during and after the reporting period

January

- Approval of Buprelab in Estonia, Hungary and Sweden. Approval of Lysoforte in Egypt and Oxylabicycline in Jordan.

February

- Labiana Pharamceuticals reaches 100 Marketing Authorizations registered worldwide.
- Approval of Buprelab in Finland and Luxembourg. Approval of Labixxin in Serbia. Launch of Moxisolv.

March

- Approval of Labiketo VET (Labixxin) in Finland and Sweden.

April

- Publication of the company's Integrated Annual Accounts Report and subsequent presentation via webcast..
- Approval of the new Repurchase Program with a maximum term until October 31, 2024..
- Approval of Lincolab in Saudi Arabia.
- Collaboration begins with the University of Santiago de Compostela for the development of antifungals.

May

- Participation in the Medcap Forum with different one to one meeting and a presentation by Manuel Ramos, CEO of Labiana, at the Discovering Meeting.
- Participation in the European Pharma Submit in Berlin.

June

- Participation in CPHI China and visit to the factories of our raw material suppliers for the Fosfomycin API.
- Signing of the agreement with VTZ Investment CO DOO Beograd to increase the capital of Veterinaski Zavod Subotica Doo by 3 million euros. This transaction represents a dilution of Labiana's stake in this subsidiary to 10% and entails the exit of this subsidiary from the consolidation perimeter of the

group, which implies the reduction of the proforma consolidated debt at the end of 2023 by 8.5 million euros, as well as the release of 0.9 million euros of guarantees from Labiana Life (division that manages animal health business).

- Celebration of the Ordinary General Shareholders' Meeting.

September

- The registration dossier for the new license Octreotide solution for injection has been finalized. It is submitted to the health authorities by Labiana and is available for licensing to third parties.
- Participation of Francisco Fernández Campos, Research and Development Director of Labiana Pharmaceuticals as moderator of a round table at the Cannabis Forum in the framework of Farmaforum 2024, Forum of the Pharmaceutical, Biopharmaceutical and Laboratory Technologies Industry.
- Labiana has positioned itself as an entity capable of releasing the commercialization of the cannabis for therapeutic purposes.

October



- Participation with a stand at the CPHI fair in Milan, a reference event in the pharmaceutical sector at international level.
- Publication of results for the first half of 2024.
- Javier Pérez Ramos, new CEO at Labiana Lifesciences. Ignacio Yáñez Minondo, former CEO, remains as a member of the Board of Directors.
- Our General Manager, Sandra Villagrasa, participates as a speaker at the "Jornada de Estrategia y Dirección de Plantas", organized by ISPE Iberia - Spain.

November

- Release of new updated Equity Story and Lighthouse coverage initiation report.

December

- Publication of the entry agreement of the ANCESMEI Family Office to complete 5% of the total capital of the Company.



9

Significant events during and after the reporting period

After closing

January



- Attendance at IPPE in Atlanta, USA to follow up business with current and potential clients in the Latin American area.
- Visit of Labiana Pharmaceuticals' technical team to IMA's facilities in China to supervise the new freeze-drying equipment before its shipment to Spain.
- Signing of distribution agreements for Labimycin LA in France and registration of Buprelab in Germany and Tolfelab in Kuwait.

February

- Participation with stand at Iberzoo/ProPet 2025.
- Launch of Otomicol, Registration of Labimycin LA in Luxembourg and KetoProPig in Costa Rica, signing of distribution agreement for Zincalab in Benelux.

March



- Attendance at the XV Anvepi Forum (National Association of Iberian Swine Veterinarians).
- Attendance at FIGAN in Zaragoza March 25-28, 2025 to follow up business with current customers from Spain and other countries.
- Purchase of 2 HPLC equipment, equipped with ultraviolet (UV), refractive index (RID) and mass (iQ) detectors.
- Launch of Lexylan, registration of Calciolab injectable solution in Greece, registration of Labiprofen in Costa Rica, signing of distribution agreement for Labimycin LA in Ireland and Buprelab in Canada.



- Participation of our CEO, Manuel Ramos, in the conference "Talent without Gender", organized by MF Manufacturing.

April

- Arrival of new freeze-drying equipment in Labiana.
- Participation of the CEO, Manuel Ramos Ortega, in the event "Investing in health: the great opportunity?", organized by Finect.



10

R&D activity and registrations

R&D and registration activities continue as normal. Regard to the registration activity, the following tables show the activity in market authorizations during the year 2024 in each of the divisions. It should be noted that 2024 closed with 6 new Market Authorizations in human health and 35 new Market Authorizations in animal health.

Human Health	Active MAs (approved) 31 dec 2024	In the pipeline 31 Dec 2024	Approved 2024	Submitted 2024	Approvables 2025	Planned submissions 2025
1. Spain	4	1	0	1	1	1
2. EU ex/Spain	21	3	1	4	1	0
3. USA	1	0	0	0	0	0
4. LATAM	17	1	1	0	1	0
5. Rest of the world	58	18	4	3	18	2
Total	101	23	6	8	21	3

Animal Health	Active MAs (approved) 31 dec 2024	In the pipeline 31 Dec 2024	Approved 2024	Submitted 2024	Approvables 2025	Planned submissions 2025
1. Spain	32	0	0	0	0	0
2. EU ex/Spain	130	2	25	14	15	13
3. USA	0	0	0	0	0	0
4. LATAM	77	6	5	5	4	4
5. Rest of the world	257	42	5	5	15	15
Total	496	50	35	24	34	32

11 Foreseeable developments

The Company is finalizing its new Strategic Plan, which could lead to new forecasts that, if necessary, will be communicated to the Market together with their respective assumptions, subject to the approval of the Board of Directors.

12 Average supplier payment period

During fiscal 2024, the company recorded an average supplier payment period of 59.34 days compared to 62.76 days in fiscal 2023.

Figures in days	31/12/2024	31/12/2023
Average supplier payment period	59.34	62.76
Paid operations ratio	58.81	60.40
Ratio of transactions pending payment	62.06	72.84

Figures in euros	31/12/2024	31/12/2023
Total payments made	43,140,730.42	35,145,639.66
Total payments pending	8,400,116.03	7,931,323.60

	31/12/2024
Average payment period - invoices paid in a period below the legal maximum	0.66
Number of invoices paid in less than the legal maximum	7,421.00
Percentage of the total number of invoices paid	0.57
Amount of invoices paid in less time than the legal maximum	28,299,868.81
Percentage of the total amount of invoices paid	0.66

13 Acquisition and disposal of treasury shares

On December 31, 2024, the Company holds treasury stock in the amount of 699,933.44 euros (206,386.25 euros at the end of the previous year) at an average market price of 2.96 euros per share (1.25 euros per share in the previous year).

Detail of treasury stock movement in 2024	Nº Shares	€/share	Amount (euros)
Balance as of 01/01/2024 (*)	165,109	1.25	206,386.25
Purchases (**)	236,378	2.20	518,420.63
Sales(**)	165,023	2.19	361,301.36
Balance as of 31/12/2024 (*)	236,464	2.96	699,933.44

(*) Quoted price at the beginning/close of the period. (**) Average price per share

14

Consolidation perimeter

The Parent Company owns, directly or indirectly, participations in several national companies and holds, directly and indirectly, the control of these companies. The Parent Company already owned the shares of the subsidiaries in previous years. However, since it was domiciled outside Spain, it was not obliged to prepare consolidated financial statements. Therefore, as of January 1, 2018, the first consolidation of the companies comprising the Group was carried out. For accounting purposes, this date coincides with the time at which a partial spin-off and merger was carried out between two of the subsidiaries described in the following section.

On June 25, 2024, Veterinarski zavod d.o.o. Subótica entered into an agreement with VTZ Investment Co Doo Beograd to increase its capital. With this capital increase, a new majority shareholder joined the company and now holds 90% of the company's capital, while Labiana's shareholding remained at 10%. As a result, Veterinaski Zavod is no longer part of the consolidation perimeter, and the data reflected in 2024 no longer include its results.

The detail of the Subsidiaries included in the consolidation perimeter for fiscal year 2024 by the full integration method is as follows::

Consolidation perimeter	% of Direct Participation	% of Indirect Participation	Consolidation Method Applied
Labiana Life Sciences, S.A.U.	100%	-	Global integration
Labiana Pharmaceuticals, S.L.U.	100%	-	Global integration
Labiana México, S.A. de C.V.	-	95%	Global integration
Zoleant ILAC	-	51%	Global integration
Ecuador-Labiana, S.A.	-	100%	Global integration

The purpose and registered offices of the investees included in the scope of consolidation as of December 31, 2024, are as follows:

- **Labiana Life Sciences, S.A.U.** Its main activity consists of the commercialization of its own veterinary products, the provision of manufacturing services of pharmaceutical and veterinary products for third parties, the provision of services aimed at the renewal of product registrations, the creation and updating of dossiers and advice on procedures with the health authorities for third parties and its own, the development of new pharmaceutical and veterinary products, and reformulations of existing products, as well as any other activity related to the corporate purpose. Its current address is in Madrid, at Avenida Europa, 34D.
- **Labiana Pharmaceuticals, S.L.U.** Its main activity consists of the manufacture and constitution of pharmaceutical products, as well as activities in the biotechnological, pharmaceutical, cosmetic, chemical and food industries. Its industrial facilities are in Corbera de Llobregat (Barcelona).
- **Labiana de México, S.A. de C.V.** Its main activity consists of the commercialization of pharmacological products and the commercialization of veterinary instruments. Its current address is in the city of Tejería (Veracruz, Mexico).
- **Zoleant ILAC.** Its main activity consists of manufacturing, research and development, marketing, storage and packaging of animal pharmaceuticals. Its current domicile is in the Republic of Turkey, being its corporate purpose.
- **Ecuador – Labiana, S.A.** Its main activity is the manufacture, research and development, marketing, storage and packaging of animal pharmaceutical products. Its current domicile is in Ecuador.

15 Labiana Health in the Stock Market

Labiana Health's stock market performance during 2024 was very satisfactory, leading BME Growth in terms of the highest market revaluation. In fact, the Labiana share closed last year with a price of 2.96 euros, which represented an increase in value of 136.8%, closing the year with a market capitalization of 21.4 million euros.

This performance contrasts very positively with the falls in the Ibex Growth Market 15 (-25.5%) and the Ibex Growth Market All Share indices. In terms of liquidity, the average daily cash volume also recorded significant growth over 2024 to reach almost 14,000 euros per day compared with an average of 4,583 euros for 2023 as a whole, i.e. 205% growth, while the average daily volume of shares traded stood at 6,477 shares, 146% more than in 2023.

To understand the factors explaining this behavior, it should be remembered that in 2023 Labiana's shares were impacted by the sale of the position of a foreign fund that participated in the company's IPO in 2022, and that in 2023 it decided to liquidate its position, which meant that it had to unwind all the positions in its portfolio. This adjustment in the share price was amplified in a stock market context of limited liquidity, combined with an inflationary macro environment with high interest rates, which affected the

price of raw materials, the supply chain and the financial cost of the company's indebtedness.

However, throughout 2024 with a more normalized environment, the market positively valued several management measures adopted by Labiana since the appointment of Sandra Villagrasa as CEO, among which can be highlighted: cost control measures, the boosting of business sales, especially in human health, the agreement signed with VTZ Investment Co Doo Beograd whereby Labiana stops consolidating its subsidiary in Serbia, Veterinaski Zavod Subotica Doo, significantly reducing its consolidated debt, the reduction of indebtedness and the restructuring of debt, all combined with a review of the Strategic Plan.

In addition, the company continued its policy of boosting Investor Relations not only through increasingly complete and detailed reporting, but also by updating the equity story or investment proposal

that was presented at the Medcap Forum in May 2024 in discovery meetings and one-on-one meetings. In addition, the intense activity on social networks to give visibility to the company's businesses in terms of initiatives and results, and the start of coverage by Lighthouse analysts who provide an independent opinion through the publication of their systematic research, should also be highlighted. In this positive context of 2024, a Share Buyback Program was approved by the Board of Directors, which also demonstrates the commitment and confidence that the management itself has in Labiana's medium and long-term growth prospects. Therefore, there is no specific explanatory factor but rather the market's reading of a series of policies and management measures successfully carried out by Labiana during 2024.

Share price (euros)	2024	2023
Open	1.25	3.36
Low	1.18	1.08
High	3.18	3.44
Close	2.96	1.25
Average	2.17	2.37


Other stock market indicators	2024	2023
Market capitalisation (euros)	21,374,914.80	9,026,568.75
Number of shares	7,221,255.00	7,221,255.00
Nominal value (euros/share)	0.1	0.1
Acumulated volume (share)	1,275,885.00	483,572.00
Average volume (share)	5,145.34	2,628.11
Accumulated turnover (euros)	2,751,948.52	843,280.19
Average turnover (euros)	9,480.25	4,583.04

Labiana Health vs Indices ¹	2024	2023
LABIANA	136.8%	(62.8%)
Ibex Growth Market 15	(25.5%)	(24.2%)
Ibex Growth Market All Share	(1.7%)	(11.0%)


1. Percentage change in closing price in the twelve months of 2023 and in the twelve months of 2024.

15 Labiana Health in the Stock Market

Labiana Health vs Ibex Growth Market 15 and Ibex Growth Market All Share
29-12-23 to 31-12-24



Labiana Health: Closing performance and volume of shares
29-12-2023 to 31-12-2024



16 Glossary

API

The active ingredient.

Regulatory Authorities

Any official administrative or governmental authority having jurisdiction within the Territory to grant Marketing Authorizations with respect to the Product.

Marketing Authorization (MA)

License granted by the relevant authority allowing the promotion, marketing, sale, importation and legal distribution of the Product in the Territory.

CapEx

Spending by a company on capital expenditures.

CDMO (Development and Contract Manufacturing)

Comprises all steps and operations involved in the development and production of Products from APIs, including pharmaceutical formulation, packaging, labeling, in-process quality control and storage of Products, APIs and Excipients, until delivery to the customer.

CMO, Contract Manufacturing, Manufacturing

All steps and operations involved in the production of Products from APIs, including pharmaceutical formulation, packaging, labeling, quality and in-process control and storage of Products, APIs and Excipients, until delivery to the customer.

Net Financial Debt (NFD)

This is the sum of long-term and short-term financial debt (including debts with credit institutions and third parties) less cash (balances in banks).

Dossier, Registration, Registration Dossier

Dossier containing all confidential scientific and technical documents and information to request the Authorization to Commercialize the Product in the Territory. The Registration Dossier is classified as confidential information.

EBIT, earnings before interest and taxes

It is calculated by subtracting the company's operating expenses from its total revenues.

Adjusted EBIT 2023

Earnings before interest and taxes deducting extraordinary expenses derived from the Miralta process and the search for advisors (advisors for the entire process).

Adjusted EBIT 2024

Earnings before interest and taxes after deducting the extraordinary expenses derived from the Miralta process, the divestment process in Serbia and the search for financing.

EBITDA, earnings before interest, taxes, depreciation and amortization

Shows the company's operating profit.

Adjusted EBITDA 2023

Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process and the search for advisors (advisors for the entire process).

Adjusted EBITDA 2024

Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process, the divestment process in Serbia and the search for financing.

Free Cash Flow

The cash flow generated by the Group's operating activities. It is calculated after deducting the investments that have been made to keep the Group's companies in operation. In short, it is the cash available after paying the corresponding expenses.

Generic

Any drug that has the same qualitative and quantitative composition in active ingredients and the same pharmaceutical form, and whose bioequivalence with the reference drug has been demonstrated by appropriate bioavailability studies. Generic drug is a drug that bases its authorization on the demonstration of bioequivalence with a previously authorized drug and for which the data protection period has expired (i.e., at least ten years have elapsed since its authorization).

GMP, Good Manufacturing Practices

The rules and regulations approved at a given time by the competent authorities of a territory or country or in other standards in relation to the manufacture, packaging, storage and quality control of pharmaceutical products.

Management Buy Out (MBO)

Process by which the executives who manage a company decide to acquire ownership of the company.

Metaphylaxis

Administration of a drug to a group of animals after diagnosis of a clinical disease in part of the group, to treat the clinically ill animals and to control transmission of the disease to closely contacted and endangered animals that may already be sub clinically infected.

Prophylaxis

A set of measures taken to protect or preserve against disease. Prophylaxis is the preventive treatment of disease.

Liquidity ratio

An indicator of a company's ability to meet its debts and short-term obligations.

Solvency ratio

Indicator that shows the capacity of a company to meet all its obligations.

Shareholder's equity

Shareholder's equity.

Return on Investment (ROI)

Measure used to know what the company earns through its investments.

Return on Capital Investment (ROIC)

A measure used to know what the company earns on invested capital.





Cristina Ramos Recoder

investors@labiana.com

(+34) 91 991 26 28

www.labiana.com

Gross Financial Debt Structure	Figures expressed in euros		
	31.12.24 WITHOUT Zavod	31.12.23 WITH Zavod	% Var. 2024 WITHOUT Zavod vs 2023 WITH Zavod
Long-term debt	27,236,690.89	30,587,784.70	(11.0)
Short-term debt	8,153,138.54	11,132,438.21	(26.8)

Capital Structure	Figures expressed in million euros		
	31.12.24 WITHOUT Zavod	31.12.23 WITH Zavod	% Var. 2024 WITHOUT Zavod vs 2023 WITH Zavod
Total Net Equity	2.57	3.40	(24.5)
Debt with credit institutions	8.44	17.78	(52.5)
Miralta/Blantyre loan	22.76	18.56	22.6
Public Administrations Loans	3.18	3.78	(16.0)
Other financial liabilities	1.01	0.95	6.6
Total Gross Financial Debt	35.39	41.07	(13.8)
Total capital structure	37.96	44.48	(14.7)
Cash and other cash equivalents	6.74	2.96	127.7
Net Financial Debt	31.22	41.52	(24.8)

